Latest Insider Transactions at Theravance Biopharma, Inc. (TBPH)
This section provides a real-time view of insider transactions for Theravance Biopharma, Inc. (TBPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Theravance Biopharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Theravance Biopharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 20
2024
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
9,268
-2.63%
|
$74,144
$8.22 P/Share
|
|
Aug 20
2024
|
Aine Miller SVP, DEV & HEAD OF IRE OFFICE |
SELL
Payment of exercise price or tax liability
|
Direct |
5,201
-3.14%
|
$41,608
$8.22 P/Share
|
|
Aug 20
2024
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
8,635
-2.62%
|
$69,080
$8.22 P/Share
|
|
Aug 20
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
15,997
-0.87%
|
$127,976
$8.22 P/Share
|
|
Aug 20
2024
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
9,222
-2.74%
|
$73,776
$8.22 P/Share
|
|
Aug 07
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,252
+0.18%
|
$22,764
$7.83 P/Share
|
|
Aug 07
2024
|
Eli Samaha > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
999,800
+9.51%
|
$6,998,600
$7.8 P/Share
|
|
Jul 10
2024
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Open market or private sale
|
Direct |
4,000
-1.18%
|
$36,000
$9.0 P/Share
|
|
May 20
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
15,997
-0.86%
|
$143,973
$9.1 P/Share
|
|
May 20
2024
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
9,268
-2.57%
|
$83,412
$9.1 P/Share
|
|
May 20
2024
|
Aine Miller SVP, DEV & HEAD OF IRE OFFICE |
SELL
Payment of exercise price or tax liability
|
Direct |
5,201
-3.04%
|
$46,809
$9.1 P/Share
|
|
May 20
2024
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
8,635
-2.55%
|
$77,715
$9.1 P/Share
|
|
May 20
2024
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
9,268
-2.65%
|
$83,412
$9.1 P/Share
|
|
May 15
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,068
+0.11%
|
$18,612
$9.85 P/Share
|
|
May 08
2024
|
Donal O'Connor |
BUY
Grant, award, or other acquisition
|
Direct |
10,537
+14.22%
|
-
|
|
May 08
2024
|
Deepika Pakianathan |
BUY
Grant, award, or other acquisition
|
Direct |
10,537
+18.18%
|
-
|
|
May 08
2024
|
Susannah Gray |
BUY
Grant, award, or other acquisition
|
Direct |
10,537
+25.07%
|
-
|
|
May 08
2024
|
Dean J Mitchell |
BUY
Grant, award, or other acquisition
|
Direct |
10,537
+11.57%
|
-
|
|
May 08
2024
|
Alsup Laurie Smaldone |
BUY
Grant, award, or other acquisition
|
Direct |
10,537
+14.07%
|
-
|
|
May 08
2024
|
Eran Broshy |
BUY
Grant, award, or other acquisition
|
Direct |
10,537
+11.57%
|
-
|
|
May 08
2024
|
Jeremy T Grant |
BUY
Grant, award, or other acquisition
|
Direct |
10,537
+32.08%
|
-
|
|
May 01
2024
|
Eli Samaha > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,499,124
+8.32%
|
$11,992,992
$8.75 P/Share
|
|
Apr 02
2024
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+22.8%
|
-
|
|
Apr 02
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+13.95%
|
-
|
|
Apr 02
2024
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+21.71%
|
-
|
|
Apr 02
2024
|
Aine Miller SVP, DEV & HEAD OF IRE OFFICE |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+17.98%
|
-
|
|
Apr 02
2024
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+9.7%
|
-
|
|
Mar 15
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
BUY
Bona fide gift
|
Indirect |
3,900
+50.0%
|
-
|
|
Mar 15
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Bona fide gift
|
Direct |
10,900
-0.35%
|
-
|
|
Mar 15
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,704
+0.17%
|
$21,632
$8.64 P/Share
|
|
Feb 22
2024
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Open market or private sale
|
Direct |
1,254
-0.4%
|
$10,032
$8.71 P/Share
|
|
Feb 20
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
37,196
-2.33%
|
$297,568
$8.92 P/Share
|
|
Feb 20
2024
|
Aine Miller SVP, DEV & HEAD OF IRE OFFICE |
SELL
Payment of exercise price or tax liability
|
Direct |
11,782
-8.11%
|
$94,256
$8.92 P/Share
|
|
Feb 20
2024
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
17,036
-6.66%
|
$136,288
$8.92 P/Share
|
|
Feb 20
2024
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
18,219
-5.5%
|
$145,752
$8.92 P/Share
|
|
Feb 20
2024
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
19,294
-5.77%
|
$154,352
$8.92 P/Share
|
|
Feb 20
2024
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
17,595
-6.32%
|
$140,760
$8.92 P/Share
|
|
Dec 21
2023
|
Jeremy T Grant |
BUY
Grant, award, or other acquisition
|
Direct |
11,768
+35.0%
|
-
|
|
Nov 21
2023
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Open market or private sale
|
Direct |
1,378
-0.41%
|
$13,780
$10.29 P/Share
|
|
Nov 20
2023
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
15,804
-0.98%
|
$158,040
$10.37 P/Share
|
|
Nov 20
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
12,630
-3.64%
|
$126,300
$10.37 P/Share
|
|
Nov 20
2023
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
7,363
-2.58%
|
$73,630
$10.37 P/Share
|
|
Nov 20
2023
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
6,187
-2.36%
|
$61,870
$10.37 P/Share
|
|
Nov 20
2023
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
7,982
-2.34%
|
$79,820
$10.37 P/Share
|
|
Nov 14
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
2,482
-0.71%
|
$24,820
$10.22 P/Share
|
|
Oct 30
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+4.12%
|
-
|
|
Oct 16
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
2,482
-0.74%
|
$22,338
$9.03 P/Share
|
|
Sep 14
2023
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
2,482
-0.73%
|
$22,338
$9.89 P/Share
|
|
Aug 22
2023
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Open market or private sale
|
Direct |
1,807
-0.53%
|
$16,263
$9.47 P/Share
|
|
Aug 20
2023
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
8,912
-3.03%
|
$80,208
$9.7 P/Share
|